(Q28314992)

2

0 references

Christopher T. Dunwiddie

3

0 references

Charles C. Persinger

4

0 references

Bernard H. Munos

5

0 references

Stacy R. Lindborg

6

0 references

Aaron L. Schacht

Nature Reviews Drug Discovery

7

0 references

publication date

19 November 2010

0 references

published in

1 reference

Prescription drug spending trends in the United States: looking beyond the turning point

cites work

1 reference

The state of innovation in drug development

31 March 2020

1 reference

Macro trends in pharmaceutical innovation

31 March 2020

1 reference

The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.

31 March 2020

1 reference

Prospects for productivity

31 March 2020

1 reference

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development

31 March 2020

1 reference

A Proof for the Queuing Formula:L= λW

31 March 2020

1 reference

Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances

31 March 2020

1 reference

Pricing medicines: theory and practice, challenges and opportunities

31 March 2020

1 reference

The prospects for "personalized medicine" in drug development and drug therapy

31 March 2020

1 reference

The value of improving the productivity of the drug development process: faster times and better decisions

31 March 2020

1 reference

The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates

31 March 2020

1 reference

31 March 2020

1 reference

Significance of the human genome sequence to drug discovery

31 March 2020

1 reference

PCSK9: a convertase that coordinates LDL catabolism

31 March 2020

1 reference

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

31 March 2020

1 reference

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

31 March 2020

1 reference

Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease

31 March 2020

1 reference

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

31 March 2020

1 reference

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study

31 March 2020

1 reference

Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders

31 March 2020

1 reference

Sodium channels and nociception: recent concepts and therapeutic opportunities

31 March 2020

1 reference

Drug discovery in jeopardy

31 March 2020

1 reference

Rebuilding the R&D engine in big pharma.

31 March 2020

1 reference

https://pubmed.ncbi.nlm.nih.gov/20168317

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Market watch : Pharma industry strategic performance: 2007-2012E.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20168317

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A more rational approach to new-product development

1 reference

https://pubmed.ncbi.nlm.nih.gov/20168317

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD3078

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

543351

1016256401

0 references

543351

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference